Next Article in Journal
Therapeutic Advances in Oncology
Previous Article in Journal
Transcriptome Analysis Reveals HgCl2 Induces Apoptotic Cell Death in Human Lung Carcinoma H1299 Cells through Caspase-3-Independent Pathway
Open AccessReview

Heme Oxygenase 1: A Defensive Mediator in Kidney Diseases

1
Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, F-75006 Paris, France
2
U1167-RID-AGE, Institut Pasteur de Lille, Inserm, Univ. Lille, F-59000 Lille, France
3
Nephrology Department, CHU Lille, Univ. Lille, F-59000 Lille, France
*
Author to whom correspondence should be addressed.
Academic Editor: Daisuke Koya
Int. J. Mol. Sci. 2021, 22(4), 2009; https://doi.org/10.3390/ijms22042009
Received: 18 January 2021 / Revised: 4 February 2021 / Accepted: 8 February 2021 / Published: 18 February 2021
(This article belongs to the Section Molecular Biology)
The incidence of kidney disease is rising, constituting a significant burden on the healthcare system and making identification of new therapeutic targets increasingly urgent. The heme oxygenase (HO) system performs an important function in the regulation of oxidative stress and inflammation and, via these mechanisms, is thought to play a role in the prevention of non-specific injuries following acute renal failure or resulting from chronic kidney disease. The expression of HO-1 is strongly inducible by a wide range of stimuli in the kidney, consequent to the kidney’s filtration role which means HO-1 is exposed to a wide range of endogenous and exogenous molecules, and it has been shown to be protective in a variety of nephropathological animal models. Interestingly, the positive effect of HO-1 occurs in both hemolysis- and rhabdomyolysis-dominated diseases, where the kidney is extensively exposed to heme (a major HO-1 inducer), as well as in non-heme-dependent diseases such as hypertension, diabetic nephropathy or progression to end-stage renal disease. This highlights the complexity of HO-1’s functions, which is also illustrated by the fact that, despite the abundance of preclinical data, no drug targeting HO-1 has so far been translated into clinical use. The objective of this review is to assess current knowledge relating HO-1’s role in the kidney and its potential interest as a nephroprotection agent. The potential therapeutic openings will be presented, in particular through the identification of clinical trials targeting this enzyme or its products. View Full-Text
Keywords: heme-oxygenase-1; heme; kidney; hemolysis; rhabdomyolysis; toxicity; ischemia reperfusion heme-oxygenase-1; heme; kidney; hemolysis; rhabdomyolysis; toxicity; ischemia reperfusion
Show Figures

Figure 1

MDPI and ACS Style

Grunenwald, A.; Roumenina, L.T.; Frimat, M. Heme Oxygenase 1: A Defensive Mediator in Kidney Diseases. Int. J. Mol. Sci. 2021, 22, 2009. https://doi.org/10.3390/ijms22042009

AMA Style

Grunenwald A, Roumenina LT, Frimat M. Heme Oxygenase 1: A Defensive Mediator in Kidney Diseases. International Journal of Molecular Sciences. 2021; 22(4):2009. https://doi.org/10.3390/ijms22042009

Chicago/Turabian Style

Grunenwald, Anne; Roumenina, Lubka T.; Frimat, Marie. 2021. "Heme Oxygenase 1: A Defensive Mediator in Kidney Diseases" Int. J. Mol. Sci. 22, no. 4: 2009. https://doi.org/10.3390/ijms22042009

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop